0000000000774972

AUTHOR

Cristina Tomarchio

showing 2 related works from this author

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

2021

Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid cancers display some controversial aspects that represent unmet medical needs. Liquid biopsy is a non-invasive approach that detects and analyzes biological samples released from the tumor into the bloodstream. With the use of different technologies, tumor cells, free nucleic acids, and extracellular vesicles can be retrieved in the serum of cancer patients and valuable molecular information can be obtained. Recently, a growing body of evidence is accumulating…

0301 basic medicinediagnosisQH301-705.5differentiated thyroid cancerReviewNeoplastic CellsMalignancymedullary thyroid cancerCatalysisInorganic ChemistryExtracellular Vesicles03 medical and health sciences0302 clinical medicineCirculating tumor cellBiomarkers TumorCirculatingmedicineHumansThyroid NeoplasmsBiology (General)Physical and Theoretical ChemistryAnaplastic thyroid cancerLiquid biopsyQD1-999Molecular BiologyThyroid cancerSpectroscopyTumorliquid biopsybusiness.industryOrganic ChemistryThyroidMedullary thyroid cancerCancerGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseComputer Science ApplicationsChemistry030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchTherapyprognosisbusinessCell-Free Nucleic AcidsBiomarkersanaplastic thyroid cancerInternational Journal of Molecular Sciences
researchProduct

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at T…

2021

Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the molecular procedure has been standardized and optimized, including the total white blood cells (WBCs) and RNA isolation methods. Here, we compare the performance of our current manual protocol to a newly semiautomatic method based on the Biomek i-5 Automated Workstations integrated with the CytoFLEX Flow Cytometer, followed by the automatic QIAsymphony system to facilitate high-throughput processing samples and reduce the hands-on time a…

OncologyMedicine (General)medicine.medical_specialtyBCR-ABL1/ABL1Q-PCRbusiness.industrychronic myeloid leukaemiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SARS-CoV-2 infectionClinical BiochemistrySample processingmolecular responseBCR-ABL1/ABL1ISChronic myeloid leukaemiaArticle<i>BCR-ABL1/ABL1<sup>IS</sup></i>R5-920Real-time polymerase chain reactionInternal medicinehemic and lymphatic diseasesMolecular ProcedureISmedicineRNA extractionbusinessDiagnostics
researchProduct